Company
Indivior
Indivior has 23 drugs tracked on RxWires: 8 post-market, 2 in Phase 3, 9 in Phase 2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| PERSERIS | Post-Market | Schizophrenia |
| Transmucosal Buprenorphine | Post-Market | Moderate to Severe Opioid-use Disorder |
| 2.0mg Buprenorphine/0.5mg Naloxone | Post-Market | Hepatic Failure |
| buprenorphine | Post-Market | Opiate-related Disorders |
| Suboxone Sublingual Film | Post-Market | Opioid Dependence |
| Sublocade | Post-Market | Opioid Use Disorder, Severe |
| TM buprenorphine | Post-Market | Opioid-use Disorder |
| Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484 | Post-Market | Opiate Dependence |
| RBP-7000 | Phase 3 | Schizophrenia |
| RBP-6000 | Phase 3 | Opioid Use Disorder |
| Buprenorphine soluble film | Phase 2 | Opioid-related Disorders |
| XP19986 CR | Phase 2 | GERD |
| Risperidone | Phase 2 | Schizophrenia |
| RBP-6300 | Phase 2 | Opioid Related Disorder |
| Buprenorphine/naloxone Film Strip | Phase 2 | Opioid-Related Disorders |
| INDV-2000 | Phase 2 | Opioid Use Disorder |
| Buprenorphine hydrochloride marketed sublingual tablet (Subutex) | Phase 2 | Opioid Dependency |
| INDV-6001 | Phase 2 | Moderate to Severe Opioid Use Disorder |
| Arbaclofen Placarbil | Phase 2 | Alcohol Use Disorder |
| INDV-6200 | Phase 1 | Opioid-use Disorder |
| [14C]IDV184001AN | Phase 1 | Opioid Use Disorder |
| Buprenorphine Injectable Solution - Part A | Phase 1 | Healthy |
| morphine sulfate | Not Applicable | Analgesic Response |
Latest
- Rbp 6000 moved to Phase 3
- Indv 2000 moved to Phase 2
- indivior filed 8-K
- Merger or Acquisition: indivior
- indivior filed 8-K
Follow Indivior on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.